Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ISRCTN58459168
ISRCTN58459168Completed未知

Pronuclear transplantation (PNT) in patients with repeated failure following assisted reproduction

adiya Clinic0 sites29 target enrollmentStarted: May 1, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
29
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
Female

Inclusion Criteria

  • •1. No less than two failed previous IVF attempts with preimplantation embryonic lethality (embryo arrest)
  • •2. Low blastulation rates
  • •3. Low number or absence of euploid embryos

Exclusion Criteria

  • •1. Fertile patients
  • •2. Fertile homosexual female couples
  • •3. Male factor infertility

Investigators

Sponsor
adiya Clinic

Similar Trials

Completed
Not Applicable
Haploidentical transplantation with post-transplant cyclophosphamide
JPRN-UMIN000018730Division of Hematology & Oncology, Department of Medicine, Kurume University School of Medicine21
Recruiting
Phase 1
Study of safety and efficacy of transplantation of platelet extracted mitochondria in heart ischemic stroke, Clinical trial phase 1 and 2
IRCT20210920052524N1Rasht University of Medical Sciences34
Completed
Unknown
Treatment of renal transplant recipients with low bone mineral density and vascular calcification: a prospective study of alendronate therapy.Kidney transplant recipients for secondary osteoporosis and vascular calcification
JPRN-jRCT1091220155Masanori Okamoto20
Recruiting
Phase 1
Phase I/II clinical trial to assess the safety and biological efficacy of treatment with virus-specific, cytotoxic T-lymphocytes from partially matched third-party unrelated donors, in stem cell transplant patients with viral reactivation unresponsive to standard therapy (R3ACT trial)
ACTRN12613000603718Western Sydney Local Health Districit30
Active, not recruiting
Not Applicable
Treatment of patients with post-transplant lymphoproliferative disorder (PILD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy (including first, second and third amendment).
EUCTR2005-000743-29-BEHeads Study Group